Milestone Pharmaceuticals Inc. — News

Milestone Pharmaceuticals NASDAQ: MIST reported early commercial traction for CARDAMYST following its mid-February launch, while advancing a pivotal Phase III study of etripamil in atrial fibrillation with rapid ventricular rate, or AFib-RVR.

marketbeat.com - 2026-08-12 11:05:30

Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.2 per share a year ago.

zacks.com - 2026-08-12 09:26:03

Over 50% of commercially insured lives in the U.S., representing a recent and significant increase, now have coverage for CARDAMYST® (etripamil) nasal spray

globenewswire.com - 2026-08-12 07:08:00

MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that it will report financial results for the second quarter ended June 30, 2026, on Wednesday, August 12, and provide a business update before the market open.

globenewswire.com - 2026-08-04 16:01:00

Milestone Pharmaceuticals (MIST) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

zacks.com - 2026-07-29 10:35:23

MONTREAL and CHARLOTTE, N. C. , July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the "Company" or "Milestone"), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the "Options") to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the "Plan"), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to the hiring of six new employees.

globenewswire.com - 2026-07-02 21:30:39

MONTREAL and CHARLOTTE, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 288,000 options (the “Options”) to purchase the Company's common shares, pursuant to the Company's 2021 Inducement Plan (the “Plan”), previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to the hiring of six new employees.

globenewswire.com - 2026-07-02 21:30:00

Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company focused on developing novel therapies for debili

gurufocus.com - 2026-06-23 09:00:00

Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript

seekingalpha.com - 2026-06-10 13:32:13

Milestone Pharmaceuticals Inc. remains a Strong Buy, despite recent volatility and a 37% stock decline since FDA approval of Cardamyst. Cardamyst's rapid-acting efficacy, expanding insurance coverage, and unique market position underpin a compelling medium-term ramp in prescriptions and revenue. International expansion and a Phase 3 trial for AFib-RVR could significantly enlarge MIST's addressable market and long-term growth prospects.

seekingalpha.com - 2026-06-09 15:38:58

MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that management will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ to take place on Tuesday, May 19, 2026 in New York.

globenewswire.com - 2026-05-14 08:30:00

The biotech fell well short of analyst projections in the first quarter.

fool.com - 2026-05-13 17:56:58

Milestone Pharmaceuticals NASDAQ: MIST said its first quarter of 2026 marked the beginning of commercial sales for CARDEMYST, its newly approved treatment for acute episodes of paroxysmal supraventricular tachycardia, or PSVT, while the company also moved ahead with a Phase 3 program in atrial fibrillation with rapid ventricular rate.

marketbeat.com - 2026-05-13 14:11:33

Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-13 13:20:57

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) reported first-quarter earnings on Wednesday before the market opened. Here's a rundown of the report.

benzinga.com - 2026-05-13 10:04:09

Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of $0.06. This compares to a loss of $0.31 per share a year ago.

zacks.com - 2026-05-13 09:20:26

MONTREAL and CHARLOTTE, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced financial results for the first quarter ending March 31, 2026, and provided corporate and regulatory updates.

globenewswire.com - 2026-05-13 07:11:00